The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients

BACKGROUND: ER+/HER2− breast cancers have a proclivity for late recurrence. A personalised estimate of relapse risk after 5 years of endocrine treatment can improve patient selection for extended hormonal therapy. METHODS: A total of 1702 postmenopausal ER+/HER2− breast cancer patients from two adju...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Dubsky, P, Brase, J C, Jakesz, R, Rudas, M, Singer, C F, Greil, R, Dietze, O, Luisser, I, Klug, E, Sedivy, R, Bachner, M, Mayr, D, Schmidt, M, Gehrmann, M C, Petry, C, Weber, K E, Fisch, K, Kronenwett, R, Gnant, M, Filipits, M
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2013
Gaiak:
Clinical Study
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3859949/
https://ncbi.nlm.nih.gov/pubmed/24157828
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.671
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak